Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimer's disease
CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Scientists at Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) have developed a synthetic model to potentially standardize the study of soluble amyloid beta oligomers (AßOs), toxic proteins that accumulate early in Alzheimer’s disease (AD). This methodology will be presented in a poster at the Alzheimer’s Association International Conference (AAIC), held in-person in San Diego and virtually between July 31 and Aug. 4, 2022.
Studies suggest toxic soluble AßOs contribute to AD-associated memory and cognitive problems. However, soluble AßOs have been challenging to model in the laboratory as their structures in the brain are difficult to characterize due to their low concentration and instability, and because they appear in various forms. To adequately study soluble AßOs, standardized analytical tools are required.
Utilizing Aß-derived diffusible ligands (ADDLs) as a synthetic AßO model may aid in standardization of AßO assays. For example, using ADDL assays to better understand the specificity and selectivity of Aß-targeting antibodies may support therapeutic development. Other expected uses for ADDLs are as a quantitative standard in assays aimed at measuring soluble AßOs or AßO auto-antibodies in patient biofluids.
“These research efforts towards developing a reliable model of AßOs will contribute to the greater body of knowledge around oligomers and Alzheimer’s disease,” said Eric Siemers, M.D., Chief Medical Officer at Acumen Pharmaceuticals. “AßOs have been a lesser studied target in Alzheimer’s disease. We expect our ongoing Phase 1 clinical trial of ACU193 to provide proof of mechanism data that we believe will shed additional light on the role of oligomers in Alzheimer’s disease.”
The poster, “Preparation and qualification of soluble amyloid beta oligomers for use in bioanalytic assays supporting Alzheimer’s disease therapeutics” (P4-17), will be presented on Wednesday, Aug. 3, 2022 and is viewable on the AAIC conference website to registrants through Sept. 2, 2022.
About Acumen Pharmaceuticals, Inc.